Literature DB >> 18550665

Replication properties of clade A/C chimeric feline immunodeficiency viruses and evaluation of infection kinetics in the domestic cat.

Sohela de Rozìeres1, Jesse Thompson, Magnus Sundstrom, Julia Gruber, Debora S Stump, Aymeric P de Parseval, Sue VandeWoude, John H Elder.   

Abstract

Feline immunodeficiency virus (FIV) causes progressive immunodeficiency in domestic cats, with clinical course dependent on virus strain. For example, clade A FIV-PPR is predominantly neurotropic and causes a mild disease in the periphery, whereas clade C FIV-C36 causes fulminant disease with CD4(+) T-cell depletion and neutropenia but no significant pathology in the central nervous system. In order to map pathogenic determinants, chimeric viruses were prepared between FIV-C36 and FIV-PPR, with reciprocal exchanges involving (i) the 3' halves of the viruses, including the Vif, OrfA, and Env genes; (ii) the 5' end extending from the 5' long terminal repeat (LTR) to the beginning of the capsid (CA)-coding region; and (iii) the 3' LTR and Rev2-coding regions. Ex vivo replication rates and in vivo replication and pathologies were then assessed and compared to those of the parental viruses. The results show that FIV-C36 replicates ex vivo and in vivo to levels approximately 20-fold greater than those of FIV-PPR. None of the chimeric FIVs recapitulated the replication rate of FIV-C36, although most replicated to levels similar to those of FIV-PPR. The rates of chloramphenicol acetyltransferase gene transcription driven by the FIV-C36 and FIV-PPR LTRs were identical. Furthermore, the ratios of surface glycoprotein (SU) to capsid protein (CA) in the released particles were essentially the same in the wild-type and chimeric FIVs. Tests were performed in vivo on the wild-type FIVs and chimeras carrying the 3' half of FIV-C36 or the 3' LTR and Rev2 regions of FIV-C36 on the PPR background. Both chimeras were infectious in vivo, although replication levels were lower than for the parental viruses. The chimera carrying the 3' half of FIV-C36 demonstrated an intermediate disease course with a delayed peak viral load but ultimately resulted in significant reductions in neutrophil and CD4(+) T cells, suggesting potential adaptation in vivo. Taken together, the findings suggest that the rapid-growth phenotype and pathogenicity of FIV-C36 are the result of evolutionary fine tuning throughout the viral genome, rather than being properties of any one constituent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550665      PMCID: PMC2519559          DOI: 10.1128/JVI.00337-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Persistent infection of macaques with simian-human immunodeficiency viruses.

Authors:  J T Li; M Halloran; C I Lord; A Watson; J Ranchalis; M Fung; N L Letvin; J G Sodroski
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Differential cell tropism of feline immunodeficiency virus molecular clones in vivo.

Authors:  G A Dean; S Himathongkham; E E Sparger
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses.

Authors:  B J Willett; L Picard; M J Hosie; J D Turner; K Adema; P R Clapham
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

5.  Sleep patterns are disturbed in cats infected with feline immunodeficiency virus.

Authors:  O Prospéro-García; N Herold; T R Phillips; J H Elder; F E Bloom; S J Henriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

7.  Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage.

Authors:  L J Diehl; C K Mathiason-Dubard; L L O'Neil; L A Obert; E A Hoover
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques.

Authors:  P Ten Haaft; B Verstrepen; K Uberla; B Rosenwirth; J Heeney
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  FIV infection of IL-2-dependent and -independent feline lymphocyte lines: host cells range distinctions and specific cytokine upregulation.

Authors:  D L Lerner; C K Grant; A de Parseval; J H Elder
Journal:  Vet Immunol Immunopathol       Date:  1998-10-23       Impact factor: 2.046

View more
  18 in total

1.  Widely conserved recombination patterns among single-stranded DNA viruses.

Authors:  P Lefeuvre; J-M Lett; A Varsani; D P Martin
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

2.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Novel gammaherpesviruses in North American domestic cats, bobcats, and pumas: identification, prevalence, and risk factors.

Authors:  Ryan M Troyer; Julia A Beatty; Kathryn R Stutzman-Rodriguez; Scott Carver; Caitlin C Lozano; Justin S Lee; Michael R Lappin; Seth P D Riley; Laurel E K Serieys; Kenneth A Logan; Linda L Sweanor; Walter M Boyce; T Winston Vickers; Roy McBride; Kevin R Crooks; Jesse S Lewis; Mark W Cunningham; Joel Rovnak; Sandra L Quackenbush; Sue VandeWoude
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

4.  FIV diversity: FIV Ple subtype composition may influence disease outcome in African lions.

Authors:  Jennifer L Troyer; Melody E Roelke; Jillian M Jespersen; Natalie Baggett; Valerie Buckley-Beason; Dan MacNulty; Meggan Craft; Craig Packer; Jill Pecon-Slattery; Stephen J O'Brien
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

5.  Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation.

Authors:  James H Morrison; Rebekah B Guevara; Adriana C Marcano; Dyana T Saenz; Hind J Fadel; Daniel K Rogstad; Eric M Poeschla
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

6.  Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection.

Authors:  Britta A Wood; Scott Carver; Ryan M Troyer; John H Elder; Sue VandeWoude
Journal:  J Immunol Methods       Date:  2013-08-14       Impact factor: 2.303

7.  Strain-specific viral distribution and neuropathology of feline immunodeficiency virus.

Authors:  Craig Miller; Helle Bielefeldt-Ohmann; Martha MacMillan; Salvador Huitron-Resendiz; Steven Henriksen; John Elder; Susan VandeWoude
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

8.  Feline models of viral pathogenesis: opportunity knocks.

Authors:  Jennifer L Troyer; Meredith A Brown
Journal:  Vet J       Date:  2010-08-15       Impact factor: 2.688

Review 9.  Molecular epidemiology of feline immunodeficiency virus in the domestic cat (Felis catus).

Authors:  Jessica J Hayward; Allen G Rodrigo
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

Review 10.  Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV.

Authors:  Sue VandeWoude; Jennifer Troyer; Mary Poss
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.